Disclosed are pyrrolodihydroisoquinolines of formula (I) wherein the substituents are as described in the specification. Compounds of the type disclosed are PDE 10 inhibitors useful in the treatment of disorders of the central nervous system, neurologic disorders, psychiatric disorders and diabetes. The compounds are also useful in the regulation of fertility.